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Antiproliferative Gold(I) Complexes
Sugar-Incorporated N-Heterocyclic-Carbene-Containing Gold(I)
Complexes: Synthesis, Characterization, and Cytotoxic
Evaluation
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Diego Tesauro,[d,e] Angela Tuzi,[a] Francesco Ruffo,[a,b] and Angela D'Amora*[a,e]
Abstract: A series of neutral and cationic gold(I) complexes
bearing a glucopyranoside-incorporated N-heterocyclic carbene
(NHC) ligand are synthetized and structurally characterized. Dif-
ferent secondary ligands (chlorido, phosphane, or sugar–NHC)
are employed to tune the properties of the complexes. The anti-
proliferative effects of the compounds are evaluated against
Introduction
Although cisplatin (CDDP) is a successful chemotherapeutic
drug for many oncological pathologies and was first approved
by the U.S. Food and Drug Administration (FDA) in 1978 for the
treatment of genitourinary tumors, it shows side-effects and
resistance can occur during the care process.[1] Therefore, the
scientific community has been engaged in the search for new
transition-metal complexes that can act as growth-inhibiting
agents towards tumor cells.[2] Among the non-platinum antitu-
mor agents, gold complexes have gained increasing attention
owing to their strong antiproliferative effects, which generally
occur through non-cisplatin-like mechanisms of action, as well
as their pharmacodynamic and pharmacokinetic properties.[3]
The first gold complex approved by the FDA in 1985
was {[2,3,4,6-tetra-O-acetyl-1-(thio-κS)--D-glucopyranosato]-
(triethylphosphane)gold(I)} (auranofin), which is used clinically
as an antiarthritis agent.[4] At the end of 2016, phase I and II
clinical studies of this compound for the treatment of chronic
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PC-3 prostate cancer cells and a panel of human tumor cell
lines. The activities of the phosphane complexes are compara-
ble to that observed for cisplatin. The combined results provide
further insights into the biological behavior of NHC–gold com-
plexes.
lymphocytic leukemia (CLL) were completed.[5] The successful
application of auranofin in medical treatments in the last dec-
ade prompted researchers to test two-coordinate gold(I) com-
plexes as antibacterial and cytotoxic agents.[6] The stability of
the complexes in vivo as well as their lipophilicities, hydrophilic-
ities, and redox properties can be tuned by the choice of auxil-
iary ligands. Ligands able to stabilize the gold(I) center include
phosphanes,[6] thiolates,[7] and N-heterocyclic carbenes
(NHCs).[8] Within this framework, NHC–gold complexes provide
the most promise, and several neutral and cationic gold carb-
ene species have been prepared and characterized in the last
few years.[8b,9,10] The mechanism of action of these compounds
is still highly debated, and recent studies[11–14] support the view
that gold carbene complexes work through the metalation of
many proteins bearing specific structural motifs for metal rec-
ognition.
The decoration of the imidazole ring of the NHC with biologi-
cally active residues or the conjugation of the NHC–AuI species
with specific aptamers enhances the activity of the com-
plexes.[14,15] In addition, carbohydrate uptake is significantly in-
creased in cancer cells; therefore, the design of glycoconjugates
has become an appealing strategy for the targeted delivery of
anticancer drugs.[16,17] Furthermore, the chemical properties of
carbohydrates are very attractive as a wide variety of substitu-
ents can be introduced[18] and multiple interaction points for
H-bond donors or acceptors can be provided.
Inspired by all of these considerations, we investigated the
design and the synthesis of four gold(I) complexes (Figure 1)
containing the sugar-incorporated NHC ligand 1-methyl-3-
(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)imidazolene (magi).
The cytotoxic properties of all of the compounds were
screened against PC-3 prostate cancer cells. The most promising
compound, [magiAuP1][BF4], was tested against a panel of hu-
man tumor cell lines.
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Figure 1. Structures of magi–AuI complexes.
Results and Discussion
Synthesis of Gold(I) Complexes
The synthesis of the gold(I) complex [magiAuCl] was performed
through the known transmetalation route with the correspond-
ing AgI complex, which was prepared according to the general
method described by Nishioka et al.,[19] and the transfer of the
magi ligand to the AuI precursor [(tht)AuCl] (tht = tetrahydro-
thiophene, Scheme 1).
Scheme 1. Synthesis of the AuI complexes [magiAuCl], [magiAuP1]BF4, and
[magiAuP2][OSO2CF3].
The complex [magiAuCl] was isolated in 90 % yield and char-
acterized through 1H and 13C{1H} NMR spectroscopy. In the
13C{1H} NMR spectrum, a significant shift was observed for the
signal corresponding to the carbene carbon atom, which
moved from δ = 139 ppm for the imidazolium salt to δ =
172.4 ppm.[20]
Crystals of [magiAuCl] suitable for XRD were obtained
through the slow evaporation of a solution of the complex in
N,N-dimethylformamide (DMF) at room temperature. The X-ray
diffraction study confirmed the identity of the compound as a
neutral mononuclear NHC–AuI complex (Figure 2). The com-
pound crystallizes in the monoclinic P21 space group with one
molecule of the complex and one solvate DMF molecule in the
independent unit.
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Figure 2. ORTEP view of [magiAuCl]. Thermal ellipsoids are drawn at the 50 %
probability level. Selected bond lengths [Å] and angles [°]: Au1–Cl1
2.3209(12), Au1–C1 1.943(8); C1–Au1–Cl1 176.8(5).
All of the bond lengths and angles in the NHC ligand are in
the normal ranges. The crystal data and structure details are
reported in the Supporting Information (Table S1). The Au–Cl
and Au–C bond lengths are consistent with those of analogous
(NHC)AuCl compounds.[21] As expected, the Au atom is linearly
two-coordinate and bonded to the central carbon atom of the
NHC ligand and the chlorine atom. The encumbered pendant
pyranose ring in the complex is in the chair conformation with
all substituents in equatorial positions. The ring is almost per-
pendicular to the imidazole plane to interact favorably with the
metal center. In the crystal packing, one interesting feature is
the presence of intra- and intermolecular Au···HCmethyl contacts
that assemble the molecules into columns running along the b
axis (Figures S1 and S2). No aurophilic interactions were found,
and the shortest intermolecular Au1···Au1 distance is
6.734(1) Å.
The two cationic carbene complexes [magiAuP1][BF4] and
[magiAuP2][OSO2CF3] (Scheme 1), were synthetized by replac-
ing the chlorido ligand with triphenylphosphane (P1) or the
glycosylated phosphane P2.[22] The procedure reported by Cas-
ini was adapted;[2] the neutral complex [magiAuCl] was dis-
solved in dichloromethane at room temperature, and the ap-
propriate amount of the phosphane ligand and a slight excess
of the silver salt as a halide abstractor were added. After the
partial evaporation of the CH2Cl2, the new cationic gold com-
plexes [magiAuP1][BF4] and [magiAuP2][OSO2CF3] were precipi-
tated with diethyl ether and isolated in high yields (up to 90 %).
In the NMR spectrum, the resonances of the sugar protons were
assigned on the basis of both their expected chemical shifts
and the coupling constants within the glucose ring. The 31P{1H}
NMR spectra of [magiAuP1][BF4] and [magiAuP2][OSO2CF3]
showed one broad singlet at δ = 40.2 and 40.4 ppm, respec-
tively, which are diagnostic of cationic gold(I)–phosphane com-
plexes.[23] Finally, the 13C{1H} NMR spectra display the character-
istic signals of the carbene carbon atom bound to a cationic
gold(I) center at δ ≈ 185 ppm, which is shifted downfield by
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Figure 3. Effect of AuI complexes and cisplatin on the total metabolic activity of PC-3 cancer cells. The PC-3 cells (4 × 103) were seeded in 96-well plates and
treated with different concentrations of the AuI complexes for 72 h. After the treatment, CCK-8 assays was performed. [magiAuP1]BF4 and [magiAuP2][OSO2CF3]
reduced the metabolic activity in a dose-dependent manner, whereas [magiAuCl] and [bis(magi)Au]BF4 showed no significant activity. Cells treated with
DMSO (0.1 %) and cisplatin (CDDP) were included for control and comparative purposes respectively [n = 3, the standard deviations (SDs) are indicated].
ca. 10–15 ppm with respect to that of halide complexes.[21a]
Furthermore, 19F NMR spectra were collected for both com-
plexes.
The treatment of a CH2Cl2 solution of the imidazolium salt
magiHBF4 containing a non-coordinating anion with silver
oxide and then (tht)AuCl resulted in the formation of
[bis(magi)AuI][BF4] in good yield (Scheme 2).[24]
Scheme 2. Synthesis of the bis(NHC)AuI complex [bis(magi)Au][BF4].
The observance of only one set of NHC signals in the 1H NMR
spectrum of [bis(magi)Au][BF4] indicates a symmetric structure,
whereas the most diagnostic feature in the 13C{1H} NMR spec-
trum is the signal at δ = 182.9 ppm, which is indicative of an
NHC–AuI bond.[25]
Cytotoxicity Assays
To investigate the abilities of the NHC–AuI complexes to the
inhibit growth of prostate cancer cells, used as a metastatic
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model, increasing amounts of complexes were added to a cell-
culture medium. Cisplatin and magiHBr were used as compara-
tive compounds (Figure 3; Table 1). At the tested concentra-
tions, the free ligand was totally inert. The decreased prolifera-
tion of PC-3 cells was obtained after treatment with 10 μM of
[magiAuP1]BF4 or [magiAuP2][OSO2CF3] (by ca. 40 and 30 %,
respectively; Figure 3). Under the same experimental condi-
tions, the compounds that do not contain phosphanes showed
half-maximal effective concentration (EC50) values more than
ten times higher (Table 1).
Table 1. EC50 values of the AuI complexes against PC-3 cell lines.
AuI complex EC50 [μM][a]
magiHBr >300 ± 0.2
[magiAuP1]BF4 9.0 ± 0.06
[magiAuP2][OSO2CF3] 10.0 ± 0.07
[magiAuCl] 100 ± 0.19
[bis(magi)Au]BF4 >100 ± 0.06
[a] Average of three independent experiments, SDs determined by crystal
violet assays (72 h incubation time). Solutions of the AuI complexes were
prepared through the dilution of freshly prepared stock solutions (10–2 M in
DMSO) of the compounds in culture medium.
The introduction of the sugar function to the phosphane
ligand did not affect the cytotoxic activity. This result provides
further evidence that this auxiliary ligand is substituted by Le-
wis bases of the molecular cellular target. The neutral chlorido
complex did not have a significant effect on tumor-cell growth.
Generally, in a similar series of carbene complexes, the EC50
values of cationic species are one order of magnitude smaller
than those of neutral complexes. The higher antiproliferative
effect is attributed to the presence of the positive charge com-
bined with the rather large lipophilic character of NHC ligands.
The dramatic effect of the charge observed in this study sug-
gests that the cationic complexes are not neutralized in the
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physiological environment and also that the lack of activity for
the neutral complexes can be attributed to poor mitochondrial
penetration.
The inertness[26] of [bis(magi)Au]BF4 can be explained on the
same basis, if it is assumed that the pathway to the mitochon-
drial target is similarly hindered. In a previous study,[11d] these
species were more reactive toward the fundamental interaction
with Thx (Thx = thioredoxin reductase).
Moreover, the antiproliferative effect of [magiAuP1]BF4 was
investigated against a panel of human cancer cells. As shown
in Table 2, the concentration to achieve a 50 % reduction in the
fold extent of proliferation was similar for all tested cell lines.
Table 2. Growth inhibition of [magiAuP1]BF4 and cisplatin against different
cell lines.
EC50 [μM][a]
PC-3 A375 U2OS MCF7
[magiAuP1]BF4 9 ± 0.06 10 ± 0.15 10 ± 0.05 14 ± 0.1
cisplatin 6 ± 0.03 6 ± 0.05 n.d. 5.7 ± 0.02
[a] Average of three independent experiments, SD determined by crystal vio-
let assay (72 h incubation time); n.d., not determined.
A comparison of the cytotoxic activities of these sugar–carb-
ene gold complexes with those of similar sugar-containing moi-
eties reported previously shows a general lower activity.[14b]
These results allow us to ascribe the nanomolar EC50 value for
the sugar–carbene complex of the Tamm group to the triazole-
tethered function.
Furthermore, cells treated with 10 μM [magiAuP1]BF4 and as-
sessed by western blot failed to show a cleavage of poly(ADP-
ribose) polymerase, a classical hallmark of apoptosis (data not
shown). Lactate dehydrogenase (LDH) is a stable enzyme
present in all cell types, and the appearance of this protein in
the extracellular milieu is a conventional marker for the loss of
membrane integrity and the presence of necrosis. For this pur-
pose, LDH release was assessed in PC-3 cells treated with differ-
ent concentrations of [magiAuP1]BF4 for 72 h. As shown in Fig-
ure 4, a significant increase by ca. 50 % was observed in cells
incubated with 10 μM [magiAuP1]BF4.
Figure 4. LDH release in PC-3 cells treated with various concentrations of
[magiAuP1]BF4 for 72 h. Treatment with 0.1 % triton for 1 h is included as
positive control. Each point represents the mean ± SD of two experiments
performed in triplicate.
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These results taken together suggest that cells treated with
[magiAuP1]BF4 undergo necrosis, which cannot be considered
only as a passive and accidental form of cell death but a pro-
grammed event, as indicated in many recent studies.[27]
Conclusions
A series of neutral and cationic sugar-incorporated NHC gold(I)
complexes with Cl, magi NHC, or phosphanes as the second
ligand were synthesized and thoroughly characterized by spec-
troscopic methods. The structure of magiAuCl was also solved
by X-ray diffraction. All of the compounds were investigated
biologically against PC-3 prostate cancer cells, and [magi-
AuP1]BF4 was tested against a panel of human tumor cell lines.
Both phosphane complexes, [magiAuP2][OSO2CF3] and [magi-
AuP1]BF4, have comparable EC50 values to that of cisplatin,
whereas the neutral complex is totally inactive. Unexpectedly,
the cationic biscarbene sugar-based complex [bis(magi)Au]BF4
is also inert.
The dramatic effects of both charge and auxiliary ligands as
well as literature data for AuI–carbene species show that the
interactions with biomolecules can be affected strongly by the
substituents od the imidazole moiety even for systems with
similar electronic and lipophilic properties.
Experimental Section
Materials and General Methods: All reagents and solvents were
obtained from commercial sources and used without any further
purification. The products were characterized by 1H, 19F, 31P, and
13C NMR spectroscopy. The spectra were recorded with Bruker
AVANCE 400 and Varian Inova 500 spectrometers, and the signals
are relative to tetramethylsilane (TMS, 1H and 13C), CCl3F (19F), and
H3PO4 (31P). All coupling constants J are quoted in Hz. The elemen-
tal analyses were performed with a Carlo Erba 1106 elemental ana-
lyzer. HAuCl4, THT, 1-methylimidazole, AgBF4, AgOSO2CF3, and Ag2O
were purchased from Sigma–Aldrich. Ligand P2,[22] (tht)AuCl,[28]
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide,[29] 1-methyl-3-
(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)imidazolium bromide[19]
(magiHBr), and [magiAgBr][19] were synthesized by the literature
procedures.
[1-Methyl-3-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)imid-
azol-2-yl]gold(I)chloride [magiAuCl]: A solution of (tht)AuCl
(0.66 mmol) in CH2Cl2 (4 mL) was added to a solution of [1-methyl-
3-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)imidazol-2-yl]silver(I)
bromide (magi)AgBr (0.66 mmol) in CH2Cl2 (4 mL), and the mixture
was stirred at room temperature overnight. After the removal of
the insoluble solids by filtration through Celite®, the solution was
concentrated, and diethyl ether was added to afford a white solid
(yield 90 %). C18H24AuClN2O9 (644.81): calcd. C 33.53, H 3.75, N 4.34;
found C 33.50, H 3.73, N 4.31. 1H NMR [400 MHz, (CD3)2SO,
298 K]: δ = 7.80 (d, 3J4′-H,5′-H = 2 Hz, 1 H, 4′-imidazolium), 7.51 (d,
3J4′-H,5′-H = 2 Hz, 1 H, 5′-imidazolium), 6.22 (d, 3J1-H,2-H = 8.8 Hz, 1 H,
1-H), 5.67 (t, 3J3-H,2-H = 9.6 Hz, 1 H, 3-H), 5.46 (t, 3J2-H,3-H = 9.6 Hz, 1
H, 2-H), 5.24 (t, 3J3-H,4-H = 9.6 Hz, 1 H, 4-H), 4.37 (m, 1 H, 5-H), 4.32
(m, 2 H, 6-H), 4.17 (s, 3 H, CH3N), 2.10 (s, 3 H, AcO), 2.08 (s, 3 H,
AcO), 2.06 (s, 3 H, AcO), 2.01 (s, 3 H, AcO) ppm. 13C{1H} NMR
[100 MHz, (CD3)2SO, 298 K]: δ = 172.4 (2′-imidazolium), 170.1, 169.5,
169.4, 169.2, 123.8, 119.0, 84.8, 72.9, 71.6, 70.9, 67.5, 61.9, 37.9, 20.5,
20.4, 20.2, 20.4 ppm.
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[magiAuP1](BF4) and [magiAuP2](OSO2CF3): A Schlenk tube was
filled with magiAuCl (0.08 mmol) and PR3 (0.085 mmol), which were
dissolved in distilled dichloromethane (2 mL). The appropriate silver
salt dissolved in methanol was added dropwise at room tempera-
ture. The reaction was continued for 1 h, during which a white
precipitate appeared and then became grey after several minutes.
After filtration through Celite®, the solution was concentrated, and
diethyl ether was added to afford a white solid (yield 90 %).
[magiAuP1]BF4: C36H39AuBF4N2O9P (958.45): calcd. C 45.11, H 4.10,
N, 2.92; found C 44.97, H 3.98, N 2.88. 1H NMR (500 MHz, CDCl3,
298 K): δ = 7.72–7.28 (m, 17 H), 5.86 (d, 3J1-H,2-H = 9.5 Hz, 1 H, 1-H),
5.55 (t, 3J2-H,3-H = 9.5 Hz, 1 H, 3-H), 5.40 (t, 3J2-H,3-H = 9.5 Hz, 1 H, 2-
H), 5.10 (t, 3J3-H,4-H = 9.5 Hz, 1 H, 4-H), 4.19 (m, 1 H, 5-H), 4.08 (m, 1
H, 6-H), 4.02 (s, 3 H, CH3N), 4.0 (m, 1 H, 6′-H),2.04 (s, 3 H, AcO), 1.99
(s, 3 H, AcO), 1.91 (s, 3 H, AcO), 1.84 (s, 3 H, AcO) ppm. 19F{1H} NMR
(376 MHz, CDCl3, 298 K): δ = 152.4 ppm. 31P{1H} NMR (162 MHz,
CDCl3, 298 K): δ = 40.3 ppm. 13C{1H}NMR [100 MHz, (CD3)2SO, 298 K,
selected data]: δ = 185.1 (2′-imidazolium), 170.6, 169.8, 169.5,
169.2,124.1, 121.0, 86.4, 75.2, 73.0, 71.8, 67.9, 61.8, 39.4, 20.8, 20.7,
20.5, 20.4 ppm.
[magiAuP2](OSO2CF3): C58H59AuF3N3O18PS (1405.11): calcd. C
49.58, H 4.38, N 2.99; found C 50.03, H 4.72, N, 2.87. 1H NMR
(400 MHz, CDCl3, 298 K): δ = 7.65–6.95 (m, 26 H), 6.09 (d, 3J1-H,2-H =
12 Hz, 1 H, 1-H magi), 5.58 (s, 1 H, 7-H OP) 5.39 (t, 3J2-H,3-H =
3J3-H,4-H = 12 Hz, 1 H, 3-H magi), 5.16 (t, 1 H, 2-H magi), 5.11
(t, 3J4-H,5-H = 12 Hz, 1 H, 4-H magi), 4.78 (d, 3J1-H,2-H = 4 Hz, 1 H,
1-H OP), 4.40–4.48 (q AB, 2JHA,HB = 12 Hz, 2 H, OCH2Ph), 4.30 (dd,
3J2-H,3-H = 12 Hz, 1 H, 2-H OP), 4.22 (m, 1 H, 6-H magi), 4.19–4.13
(m, 2 H, 5-H, 6′-H magi), 4.11 (dd, 2J6-H,6′-H = 4, 3J6-H,5-H = 9.2 Hz, 1
H, 6-H OP), 4.05 (t, 1 H, 3-H OP), 3.98 (s, 3 H, CH3N), 3.87 (m, 1 H,
5-H OP), 3.72 (t, 1 H, 4-H OP) 3.52 (t, 1 H, 6′-H OP) 2.01 (s, 3 H, AcO),
2.0 (s, 3 H, AcO), 1.99 (s, 3 H, AcO), 1.97 (s, 3 H, AcO) ppm.
13C{1H}NMR (100 MHz, CDCl3, 298 K, selected data): δ = 185.6 (2′-
imidazolium), 170.6, 169.6, 169.4, 169.0, 168.4, 101.8, 97.0, 85.8, 80.8,
74.6, 72.4, 71.3, 68.7 (2), 67.4, 63.0, 61.2, 55.6, 38.9, 20.7, 20.5 (2),
20.0 ppm. 19F{1H} NMR (376 MHz, CDCl3, 298 K): δ = –77.75 ppm.
31P{1H} NMR (162 MHz, CDCl3): δ = 40.42 ppm.
1-Methyl-3-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)imid-
azolium Tetrafluoroborate (magiHBF4): A round-bottomed flask
was filled with magiHBr and NaBF4 (0.65 mmol) in acetone (20 mL).
The reaction was maintained at room temperature overnight. After
the removal of the acetone under vacuum, the obtained white solid
was partially dissolved in dichloromethane (30 mL), and filtration
through paper afforded a colorless solution. The dichloromethane
was then evaporated under vacuum to yield the pure product (98 %
yield). C19H28BF4N2O9 (515.24): calcd. C 44.29, H 5.48, N 5.44;
found C 44.25, H 5.44, N 5.39. 1H NMR (400 MHz, CDCl3, 298 K): δ =
9.55 (s, 1 H, 2′-imidazolium), 7.60 (bt, 1 H, 4′-imidazolium), 7.52
(bt, 1 H, 5′-imidazolium), 6.15 (d, 3J1-H,2-H = 9.2 Hz, 1 H, 1-H), 5.43 (t,
3J3-H,2-H = 9.6 Hz, 1 H, 3-H), 5.30 (t, 3J2-H,1-H = 9.2 Hz, 1 H, 2-H), 5.23
(t, 3J3-H,4-H = 9.6 Hz, 1 H, 4-H), 4.21 (m, 3 H), 4.03 (s, 3 H, CH3N), 2.05
(s, 3 H, AcO), 2.02 (s, 3 H, AcO), 1.98 (s, 3 H, AcO), 1.97 (s, 3 H, AcO)
ppm. 13C{1H} NMR (100 MHz, CDCl3, 298 K): δ = 170.8, 170.0, 169.9,
169.68, 137.3 (2′-imidazolium), 124.5, 120.0, 84.3, 75.0, 72.5, 70.6,
67.5, 61.6, 37.1, 20.8, 20.7, 20.6, 20.4 ppm. 19F{1H} NMR (376 MHz,
CD2Cl2, 298 K): δ = 150.6 ppm.
{Bis[1-methyl-3-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)-
imidazol-2-yl]}gold(I) Tetrafluoroborate [bis(magi)AuI](BF4): A
round-bottomed flask was filled with magiHBF4 (0.20 mmol), Ag2O
(0.16 mmol), and molecular sieves 4 Å (MS 4 Å, 100 mg) in dichloro-
methane (12 mL). The reaction proceeded for 4 h at room tempera-
ture in the dark. Then, a solution of (tht)AuCl (0.10 mmol) in di-
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chloromethane (3.4 mL) was added dropwise to the previous mix-
ture, and the reaction proceeded overnight at room temperature in
the dark. After filtration through Celite®, the volatiles were removed
under vacuum to afford the product as a white solid (60 % yield).
C36H48AuBF4N4O18 (1108.55): calcd. C 39.00, H 4.36, N 5.05; found C
38.96, H 4.32, N 4.98. 1H NMR [400 MHz, (CD3)2SO, 298 K]: δ = 7.87
(d, 3JH,H = 1.6 Hz, 1 H, 4′-imidazolium), 7.62 (d, 3JH,H = 1.6 Hz, 1 H,
5′-imidazolium), 6.29 (d, 3JH,H = 8.4 Hz, 1 H, 1-H), 5.62 (t, 3JH,H =
9.6 Hz, 1 H, 3-H), 5.57 (t, 3JH,H = 9.6 Hz, 1 H, 2-H), 5.25 (t, 3JH,H =
9.2 Hz, 1 H, 4-H), 4.37 (m, 1 H, 5-H), 4.32 (m, 2 H, 6-H), 3.95 (s, 3 H,
CH3N), 2.05 (s, 3 H, AcO), 2.01 (s, 3 H, AcO), 1.99 (s, 3 H, AcO), 1.92
(s, 3 H, AcO) ppm. 13C{1H} NMR [100 MHz, (CD3)2SO, 298 K]: δ =
182.9 (2′-imidazolium), 170.0, 169.5, 169.4, 168.7, 124.4, 119.6, 84.9,
73.2, 71.8, 70.6, 67.6, 61.9, 37.9, 20.5, 20.4, 20.2 ppm. 19F{1H} NMR
[376 MHz, (CD3)2SO2, 298 K]: δ = 148.2 ppm.
X-ray Diffraction Analysis: Colorless block-shaped single crystals
of [magiAuCl] were obtained by the slow evaporation of a DMF
solution at ambient temperature. A selected crystal was mounted
in flowing N2 at 173 K in a Bruker-Nonius KappaCCD diffractometer
equipped with an Oxford Cryostream apparatus (graphite-mono-
chromated Mo-Kα radiation, λ = 0.71073 Å, CCD rotation images,
thick slices, φ and ω scans to fill the asymmetric unit). Semiempiri-
cal absorption corrections (SADABS)[30] were applied. The structure
was solved by direct methods (SIR97 program)[31] and refined aniso-
tropically by the full-matrix least-squares method on F2 against all
independent measured reflections with SHELXL-2016/6 in the
SHELX package.[32] All hydrogen atoms were introduced in calcu-
lated positions and refined in a riding model with Uiso(H) equal to
1.2Ueq or 1.5Ueq(Cmethyl) of the carrier atom. The final refinements
converged to R1 = 0.0291 and wR2 = 0.0773. DMF solvate molecules
were present in the crystal. In the presence of strong anomalous
scattered atoms, it was possible to determine the R/R/S/R/R abso-
lute configuration at the five stereocenters C4/C5/C6/C7/C8, which
agreed with that expected from the synthetic procedures. The fig-
ures were generated with the ORTEP-3[33] and Mercury CSD 3.3[34]
programs.
CCDC 1548641 (for [magiAuCl]) contains the supplementary crystal-
lographic data for this paper. These data can be obtained free of
charge from The Cambridge Crystallographic Data Centre.
Cell Culture: Human prostate cancer cells (PC-3) were maintained
in RPMI 1640 medium (GIBCO, USA), and human malignant mela-
noma cells (A375), human osteosarcoma cells (U2OS), and human
breast carcinoma cells (MCF-7) were maintained in Dulbecco's mod-
ified Eagle's medium (DMEM; GIBCO, USA). Both media were supple-
mented with 10 % fetal bovine serum (GIBCO, USA) and 1 % L-
glutamine (Lonza, Belgium) at 37 °C in a 5 % CO2 humidified atmos-
phere and harvested at approximately 90 % confluence.
Cell-Based Assays: For cell growth studies, 4 × 103 cancer cells
were seeded in 96-well flat-bottom microplates (50 μL of medium
per well) and incubated overnight to allow cell adhesion. Subse-
quently, the culture medium was removed, and the cells were incu-
bated with their growth medium (100 μL) with increasing concen-
trations of compound, appropriately diluted with dimethyl sulfoxide
(DMSO), in quadruplicate for 72 h. The metabolic activities of cells
was determined with a cell-counting Kit 8 (CCK-8) assay, for which
the instructions provided by the manufacture (Dojindo Lab, Japan)
were followed. The CCK-8 solution (10 μL) was added directly to the
culture wells, which were incubated for 2 h at 37 °C in a 5 % CO2
humidified atmosphere. Finally, the absorbance was measured at
λ = 450 nm with a microplate reader (Multiskan Fc 10094, Thermo).
The reduction of the cell viability was determined by crystal violet
assay. Shortly after treatment, the culture medium was removed,
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and the cells were washed with phosphate-buffered saline (PBS)
and then fixed and stained with 0.1 % (w/v) crystal violet in 25 %
methanol for 30 min in the dark. The crystal violet was removed,
and the cells were washed twice with double distilled water and
left to dry. Then, the cells were solubilized by the addition of 10 %
(v/v) acetic acid, and the amount of dye taken up was quantified
with a plate reader at λ = 595 nm. The EC50 values were calculated
with the GraphPad Prism 5 software. The data were expressed as
the mean ± SD for three independents experiments.
Lactate Dehydrogenase Assay: The level of extracellular LDH re-
leased from damaged cells was measured as an indicator of the
cytotoxicity. Cells (4 × 103/well) was seeded in complete medium
and treated with 1, 10, and 50 μM [magiAuP1]BF4 for 72 h. The cells
were also treated with 0.1 % Triton X 100 as a positive control.
Untreated cells were used as a negative control. The lysates and
supernatant aliquots were then incubated with reaction buffer
[0.7 mM p-iodonitrotetrazolium violet, 50 mM L-lactic acid, 0.3 mM
phenazine methosulfate, 0.4 mM nicotinamide adenine dinucleotide
(NAD), 0.2 M tris(hydroxymethyl)aminomethane hydrochloride (Tris/
HCl) pH 8.0] for 30 min at 37 °C. The absorbance was read at λ =
490 nm with a microplate reader (Thermo, Multiskan Fc). The per-
centage of LDH released was calculated as the absorbance in the
medium of the treated cells divided by the absorbance in the me-
dium of treated cells plus the absorbance in the total pellet of
treated cells.
Supporting Information (see footnote on the first page of this
article): X-ray crystallographic data.
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